Allstate Corp vs Amgen, Inc. — how do they compare? Allstate Corp trades at $262 (market cap $66.31B), while Amgen, Inc. trades at $412.21 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 3.4× Allstate Corp's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| ALL | AMGN | |
|---|---|---|
Market Cap | $66.31B | $224.14B |
Sector | Financials | Health |
52-Week High | $275.11 | $417.20 |
52-Week Low | $190.00 | $271.18 |
Enterprise Value | $74.96B | $267.45B |
Dividend Yield | 1.65% | 2.43% |
Trailing returns across standard periods
Latest headlines on both assets
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →